Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy

Azacitidine (AZA) is a DNA methyltransferase inhibitor and epigenetic modulator that can be an effective agent in combination with chemotherapy for patients with high‐risk acute myeloid leukemia (AML). However, biological factors driving the therapeutic response of such hypomethylating agent (HMA)‐b...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Guanghao, Wang, Linchen, You, Qiancheng, Cahill, Kirk, Chen, Chuanyuan, Zhang, Wei, Fulton, Noreen, Stock, Wendy, Odenike, Olatoyosi, He, Chuan, Han, Dali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427370/
https://www.ncbi.nlm.nih.gov/pubmed/37271891
http://dx.doi.org/10.1002/advs.202300445

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427370/
https://www.ncbi.nlm.nih.gov/pubmed/37271891
http://dx.doi.org/10.1002/advs.202300445

Ejemplares similares